Pharmaceuticals News

ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical data of its...

Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation Presentations on CLYM116 and budoprutug programs highlight...

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026

New immune data from the phase 2 trial with EVX-01 to be presented both in an oral and poster presentationNew data follows from the three-year clinical update for EVX-01 to be provided at the European...

Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencelOne clinical...

NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026

Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1...

The published review examines dopamine’s role in tic generation and how approved and investigational drugs may affect dopamine to reduce tics as well as synthesizes clinical trial evidence that...